Telix boosts FY 2025 revenue guidance after strong Q3 performance

Telix Pharmaceuticals Limited announced unaudited group revenue of $206 million for Q3 2025, marking a 53% year-over-year increase. Following this strong performance, the company has raised its FY 2025 revenue guidance to a range of $800 million to $820 million, up from the previous guidance of $770 million to $800 million.

Key drivers for the Q3 results include PSMA imaging revenue of $155 million and RLS third-party revenue of $47 million. Gozellix® is now fully reimbursed by CMS with Level II HCPCS code and Transitional Pass-Through payment status effective October 1, 2025, and Illuccix® has been approved in 19 European markets and the UK, with commercial launches underway in several countries.

Telix also confirmed an expected year-over-year increase in research and development expenditure for FY 2025, ranging from 20% to 25% compared to FY 2024. The final royalty payment of $51.7 million to ANMI, reflecting strong Illuccix® sales, was made in July 2025 and will be included in H2 2025 cash flows.